SK Acquires BMS Irish Plant To Support Global CMO Leadership Ambitions
SK Biotek's acquisition of BMS's small molecule API manufacturing plant in Ireland underlines South Korean conglomerate SK Group’s stepped up efforts to grow its biotech and pharma business. The move is in line with SK Biotek's plan to sharply raise revenue and corporate value in the coming years, and the CMO is also considering additional acquisitions or collaborations.
You may also be interested in...
With the acquisition of US-based contract development and manufacturing organization AMPAC Fine Chemicals, SK has added the US production base to its European and Korean production facilities, placing it on track to becoming a top global CDMO player with annual production capacity of about 1.6 million liters.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.